1451194-69-6
Chemical Structure
Linoleoyl ethanolamide-d4
- CAS No.: 1451194-69-6
- Formula:C20H33D4NO2
- Molecular Weight:327.54
IUPAC Name: (9Z,12Z)-N-(2-hydroxyethyl-1,1,2,2-d4)octadeca-9,12-dienamide
InChIKey: KQXDGUVSAAQARU-UKNLGWMGSA-N
SMILES: CCCCC/C=C\C/C=C\CCCCCCCC(NC([2H])([2H])C([2H])([2H])O)=O
Biological Activity: Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide[1]. Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time[2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Linoleoyl ethanolamide-d4 | 99.15% | Linoleoyl ethanolamide-d4 is a deuterated labeled Linoleoyl ethanolamide. Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Linoleoyl ethanolamide | 99.98% | Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Wang X, et al. X. Synthesis of linoleoyl ethanolamide. J Oleo Sci. 2013;62(6):427-433. [Content Brief]
- [3]. Lin S, et al. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem. 1998;41(27):5353-5361. [Content Brief]
